1. Home
  2. NOMD vs ORKA Comparison

NOMD vs ORKA Comparison

Compare NOMD & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nomad Foods Limited

NOMD

Nomad Foods Limited

N/A

Current Price

$10.35

Market Cap

1.8B

ML Signal

N/A

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

N/A

Current Price

$34.33

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NOMD
ORKA
Founded
2014
2004
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
NOMD
ORKA
Price
$10.35
$34.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
10
Target Price
$14.25
$52.70
AVG Volume (30 Days)
1.7M
282.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
6.69%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.36
N/A
P/E Ratio
$8.38
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.82
$5.49
52 Week High
$20.22
$36.53

Technical Indicators

Market Signals
Indicator
NOMD
ORKA
Relative Strength Index (RSI) 26.20 55.02
Support Level N/A $31.43
Resistance Level $12.36 $36.52
Average True Range (ATR) 0.35 1.95
MACD -0.18 -0.04
Stochastic Oscillator 15.80 57.43

Price Performance

Historical Comparison
NOMD
ORKA

About NOMD Nomad Foods Limited

Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distribution of branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Scandinavia, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: